When there are borderline features, molecular assessment for the presence of additional mutations, such as CDKN2A or TERT-p, and chromosomal CNA can be helpful in differentiating low-CSD melanomas from intermediate lesions. The gene discussed is CDKN2A; the disease is melanoma.